Company Description
Entremed Inc. The Group's principal activity is to sponsor and conduct research and development of therapeutics primarily for the treatment of cancer. The Group's lead drug candidate Panzem(R) (2-methoxyestradiol or 2ME2) is currently being tested ...
More
Related Business Topics
0-9 |
A |
B |
C |
D |
E |
F |
G |
H |
I |
J |
K |
L |
M |
N |
O |
P |
Q |
R |
S |
T |
U |
V |
W |
X |
Y |
Z
E
EntreMed
EntreMed's mission as the Angiogenesis company is to discover, develop and commercialize antiangiogenic therapeutics which have the potential to treat diseases associated with angiogenesis including cancer and blindness.
www.entremed.com
EntreMed's mission as the Angiogenesis company is to discover, develop and commercialize antiangiogenic therapeutics which have the potential to treat diseases associated with angiogenesis including cancer and blindness.
www.entremed.com
Breaking News
Reuters - Nov. 16, 2009, 11:15 AM
Forbes.com - Nov. 3, 2009, 5:14 AM
Forbes.com - Oct. 22, 2009, 6:03 AM
